Enzo Biochem (NYSE:ENZ) Now Covered by StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Enzo Biochem (NYSE:ENZ) in a note issued to investors on Sunday. The brokerage set a “hold” rating on the medical research company’s stock.

Enzo Biochem Price Performance

ENZ opened at $1.12 on Friday. The stock’s 50-day moving average price is $1.12 and its 200 day moving average price is $1.13. Enzo Biochem has a 12-month low of $0.99 and a 12-month high of $1.50.

Hedge Funds Weigh In On Enzo Biochem

An institutional investor recently raised its position in Enzo Biochem stock. XTX Topco Ltd raised its stake in Enzo Biochem, Inc. (NYSE:ENZ) by 94.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,262 shares of the medical research company’s stock after purchasing an additional 13,735 shares during the period. XTX Topco Ltd owned about 0.05% of Enzo Biochem worth $31,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 36.90% of the company’s stock.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.